Statement of Changes in Beneficial Ownership (4)
September 02 2021 - 1:49PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
DOCHERTY JOHN MARTIN |
2. Issuer Name and Ticker or Trading Symbol
Lexaria Bioscience Corp.
[
LEXX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) President |
(Last)
(First)
(Middle)
23 MIKELEN DRIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/1/2021 |
(Street)
PORT PERRY, A6 L9L 1V1
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
common shares | | | | | | | | 54075 | I | Private Holding Company |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Options | $9.6 | | | | | | | 4/23/2020 | 4/23/2025 | Common Shares | 13334 | | 13334 | D | |
Stock Options | $5.31 | | | | | | | 4/26/2021 | 4/26/2026 | Common Shares | 18000 | | 31334 | D | |
Stock Options | $7.08 | | | | | | | 6/8/2021 | 6/8/2026 | Common Shares | 18334 | | 49668 | D | |
Stock Options | $6.23 | 9/1/2021 | | A | | 15000 | | 9/1/2021 | 9/1/2026 | Common Shares | 15000 | $0 | 64668 | D | |
Explanation of Responses: |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
DOCHERTY JOHN MARTIN 23 MIKELEN DRIVE PORT PERRY, A6 L9L 1V1 | X |
| President |
|
Signatures
|
/John Docherty/ | | 9/2/2021 |
**Signature of Reporting Person | Date |
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Sep 2023 to Sep 2024